Preclinical CROSequent Development is an independent preclinical CRO based in the U.S. that conducts drug studies in state-of-the art, GLP-certified research facilities in Kiev, Ukraine. Our preclinical research sites are sponsored by the Ukraine National Academy of Medical Sciences and Ministry of Health & offer support for commercial development of new drug discoveries as part of their core mission. Sequent was founded to bring the high quality, lower cost preclinical services of these research sites to emerging biotech companies… read more. |
Preclinical ServicesWe offer both GLP-compliant preclinical toxicology in vivo studies for INDs as well as non-GLP toxicology and pharmacology in vivo and in vitro studies in order to provide preliminary assessment of a drug’s safety and efficacy. Our in vivo preclinical services include pharmacokinetics, safety pharmacology, toxicology and efficacy trials. We have expertise in a range of diseases and disorders including oncology, diabetes, cardiovascular disease, neurological disorders, pain, analgesics, wound healing… read more. |
Cost AdvantageWe are able to price our services below other CROs because we maintain a very low overhead in the U.S. and conduct all preclinical studies in Kiev where labor and facility costs are lower. Our staff in the U.S. consists only of the company principals who work directly with customers; we have no marketing expenses other than our web site, and no central offices, administrative staff or other overhead to inflate prices. We have lower study conduct costs in Kiev due to lower labor rates and are able to offer our best pricing for longer… read more. |
